TITLE

Docs Losing War on AIDS

AUTHOR(S)
Carter, Tom
PUB. DATE
July 2001
SOURCE
Insight on the News;07/02/2001, Vol. 17 Issue 25, p30
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reveals that a complicated therapy of protease inhibitors and antiretroviral drugs have failed to treat HIV/AIDS infections among the population of Africa and developing countries. Adaptation and mutation of the AIDS virus into drug-resistant strains; Lack of a health-care infrastructure in Africa; Estimated funds needed to eradicate AIDS in Africa.
ACCESSION #
4764468

 

Related Articles

  • From the Archives of The Advocate. Romesburg, Don // Advocate;05/23/2000, Issue 812, p22 

    Reports on the use of protease inhibitors to treat AIDS. Side effects; Complications of patients whose lives have been extended by treatment; Coverage of the development by `Advocate' magazine.

  • Factors Associated with Poor Immunologic Responses Despite Viral Suppression in Markedly Immunosuppressed Patients. Collazos, Julio; Asensi, Víctor; Cartón, José Antonio // AIDS Patient Care & STDs;Jun2007, Vol. 21 Issue 6, p378 

    To determine the factors associated with poor immunologic responses despite viral suppression in markedly immunocompromised patients (≤200 CD4 cells per microliter at baseline), individuals with less than 100 CD4 increases after 12 months of nelfinavir-based highly active antiretroviral...

  • Diabetes, protease-inhibitor link unproved: directorate.  // CMAJ: Canadian Medical Association Journal;09/01/97, Vol. 157 Issue 5, p502 

    States that the Therapeutic Drugs Directorate at Health Canada find no conclusive evidence to support a causal relationship between protease inhibitors and diabetes or hyperglycemia in HIV-infected patients.

  • Combination of two protease inhibitors reduces HIV viral load by 99.9%.  // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p375 

    Reports on the reduction of HIV viral load of 99.9 percent by combining two protease inhibitors. Effects of the protease inhibitors.

  • Compliance and dosage critical in HIV suppression by protease inhibition.  // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p377 

    Reports that starting and maintaining protease inhibitor therapy at the recommended dosages delays the development of resistant HIV virus and assists in long-term viral suppression. Presentation of indinavir (Crixivan) data.

  • Editorial Response: Discordance between Virological, Immunologic, and Clinical Outcomes of Therapy with Protease Inhibitors among Human Immunodeficiency Virus-Infected Patients. Goetz, Matthew Bidwell // Clinical Infectious Diseases;12/1/1999, Vol. 29 Issue 6, p1431 

    Comments on the findings of I. Mezzaroma, M. Carlesimo, E. Pinter et al on the occurrence of discordant virological and immunologic responses among HIV-infected patients who had received protease inhibitor-based antiretroviral therapy, published in the December 1999 issue of the journal...

  • Ritonavir for advanced HIV infection.  // American Family Physician;7/1/1996, Vol. 54 Issue 1, p372 

    Reports that the United States Food and Drug Administration has approved the protease inhibitor ritonavir for the treatment of patients with human immunodeficiency virus (HIV) infection. Combination of ritonavir with nucleoside analogs or as monotherapy; Clinical trials on the efficacy of...

  • Invirase resistance/cross-resistance data released.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p185 

    Reveals the sensitivity of AIDS patients receiving Invirase to ritonavir and indinavir. Distinct and consistent pattern of mutation of invirase.

  • Initial Therapy with Protease Inhibitor--Sparing Regimens: Evaluation of Nevirapine and Delavirdine. Conway, Brain // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS130 

    Evaluates the results of randomized clinical trials of protease inhibitor-sparing regimens in drug-naive patients. Mean decrease in plasma viral load in patients receiving the zidovudine, didanosine and nevirapine combined therapy; Increased CD4 T cell count, indicating the immunologic benefit...

  • HIV Protease Inhibitor--Related Lipodystrophy Syndrome. Carr, Andrew // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS135 

    Explores the association of HIV protease inhibitor (PI) therapy with lipodystrophy syndrome. Occurrence of peripheral lipoatrophy during the course of the therapy; Asymptomatic and nonketotic clinical presentation in diabetes associated with PI therapy; Abnormal lipodystrophy and metabolic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics